Brief: Sutro Biopharma Announces Updated Data From Phase 1B Study Of Luvelta In Combination With Bevacizumab At Esmo 2024
14/09/2024 08:06
Sept 14 (Reuters) - Sutro Biopharma Inc STRO.O :
* SUTRO BIOPHARMA ANNOUNCES UPDATED DATA FROM PHASE 1B STUDY
OF
LUVELTA IN COMBINATION WITH BEVACIZUMAB AT ESMO 2024
* SUTRO BIOPHARMA INC - LUVELTA PLUS BEVACIZUMAB SHOWS 56%
RESPONSE RATE IN LATE-STAGE OVARIAN CANCER
* SUTRO BIOPHARMA INC - LUVELTA PLUS BEVACIZUMAB SHOWS 35%
RESPONSE RATE ACROSS ALL DOSES
Source text for Eikon: ID:nGNX3ggctn
Further company coverage: STRO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Sutro Biopharma
See all newsBrief: Sutro Biopharma Announces First Patient Dosed In Phase 1 Trial Of STRO-006
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte, CoreWeave
U.S. STOCKS ON THE MOVE-Sutro Biopharma, Humacyte
Sutro Biopharma Inc reports results for the quarter ended June 30 - Earnings Summary
Sutro Biopharma tumbles after missing estimates